A 32-year-old man sustains a 40% TBSA flame burn with inhalation injury. He is intubated in the ICU. On day 3, he develops fever (38.5°C), purulent sputum, and a new infiltrate on chest X-ray. What is the drug of choice for empiric coverage of inhalation injury-associated pneumonia in burn patients?

Explanation

## Inhalation Injury and Burn Pneumonia **Key Point:** Inhalation injury in burn patients predisposes to early respiratory infection with gram-negative organisms (Pseudomonas aeruginosa, Acinetobacter) and gram-positive cocci. Empiric coverage must be broad and include anti-pseudomonal agents. **High-Yield:** Piperacillin-tazobactam is the preferred empiric agent for suspected inhalation injury-associated pneumonia because it provides: - Broad gram-negative coverage (including Pseudomonas) - Gram-positive coverage - Anaerobic coverage - Beta-lactamase inhibition ### Rationale for Drug Choice | Feature | Piperacillin-tazobactam | Ceftriaxone | Vancomycin | Fluoroquinolone | |---------|------------------------|-------------|-----------|----------------| | Pseudomonas coverage | ✓ | ✗ | ✗ | ✓ (but monotherapy inadequate) | | Gram-positive | ✓ | ✓ | ✓ | ✓ | | Anaerobic | ✓ | ✓ | ✓ | ✗ | | First-line in burns | ✓ | ✗ | ✗ (reserve for MRSA) | ✗ | **Clinical Pearl:** Inhalation injury increases risk of early-onset (day 2–5) ventilator-associated pneumonia (VAP) with atypical organisms. Piperacillin-tazobactam covers the most common pathogens without requiring combination therapy. **Mnemonic:** **PIPTAZO** = **P**seudomonas, **I**nhalation injury, **P**erfect choice; **TAZO** = **T**azobactam (beta-lactamase inhibitor) **A**dds **Z**ero resistance, **O**ptimal coverage. [cite:ATLS 10th Edition Ch 7]